Nurix Therapeutics, Inc.
corporate_fare Company Profile
Nurix Therapeutics, Inc. (NASDAQ:NRIX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for NRIX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-03, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 10/10, with 15 rated 8 or above. Recent SEC coverage for NRIX spans 8-K, 10-Q, 424B5.
Recent high-impact activity:
- Sanofi Terminates SAR448272 STAT6 Degrader Program, Ending Nurix Milestone Stream
- Sanofi Kills Phase 1 STAT6 Degrader, Wiping Out Nurix's SAR448272 Milestones
- Nurix Q3: $549.8M Profit on Roche Upfront, $1.1B Cash, Bexobrutideg Enters Phase 3
- Nurix Posts $549.8M Q3 Profit on Roche Upfront, Advances Bexobrutideg into Phase 3
- Nurix Posts Surprise $4.73 Q3 Profit, Defying Loss Expectations
Financial Snapshot
Short Interest & Short Volume
7.17 days to coverFINRA reported short interest of 18,936,583 shares in NRIX as of the October 30, 2026 settlement, a 8.1% decrease from the prior period — about 7.2 days to cover at its recent average daily volume. On November 19, 2026, 23.3% of NRIX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.